Introduction
The underlying cause of cerebral venous thrombosis transition at nucleotide position 20210, and is a potential risk factor for the development of CVT.3 (CVT) remains uncharacterized in 20% of cases.
Deficiencies of protein C, S and antithrombin due
Severe hyperhomocysteinaemia is found in homocystinuria which, in its classical form, is due to to mutations in genes that encode these proteins are well-recognized causes of venous thrombosis, but homozygosity for cystathionine synthase and is a recognized cause of both venous and arterial thromare uncommon and account for less than 10% of cases. More recently, a poor anticoagulant response bosis. Mild hyperhomocystinaemia can be the consequence of an intermediate deficiency of one of the of plasma to activated protein C (APC) due to the presence of a point mutation in the factor V gene involved enzymes such as MTHFR. The existence of a mutation of the MTHFR gene has been demon-(factor V Leiden, FVL) has been found to be present in 20-40% of patients with familial thrombophilia, strated: a C T substitution at nucleotide 677 reduces the specific activity of the enzyme to 50% of the compared with a frequency of 5% in the normal population: recent reports suggest a 20% incidence normal in homozygotes and may increase the risk of venous thrombosis,4 although other groups have in patients with CVT.1 A genetic variation in the 3∞ untranslated (UT) region of the prothrombin gene is not confirmed these results.5 We retrospectively reviewed 15 patients with CVT who presented to associated with an elevated plasma prothrombin level and a 2.8-fold increased risk of venous thromour unit, for the incidence of these inherited and acquired prothrombotic risk factors. bosis:2 the genetic variation responsible is a G A from the South Wales population. No patients were
Methods and Results
found to have the prothrombin gene mutation allele Fifteen patients admitted to the neurology unit 20201A compared with 4/300 (1%) healthy controls between 1990 and 1997 were identified who had who were heterozygous for the mutation. Four of 14 investigation-proven CVT. Nine patients received intravenous heparin followed on arrival at our centre were altered levels of by oral anticoagulation with warfarin for a variable consciousness, papilloedema, ophthalmoplegia, parperiod of time. Patient 13 remains on warfarin for esis and extensor plantar responses.
her protein C deficiency and lupus anticoagulant. Patients 4 was prescribed aspirin, and patient 9
Method of diagnosis received no treatment due to the chronicity of the The time from the initial symptoms to definite symptoms and mild papilloedema. Patients 2 and 13 diagnosis ranged from about 12 h to 18 months developed progressive visual failure despite intraven-(patient 4). The diagnostic test was computerized ous heparin. Patient 2 had a lumbar peritoneal shunt tomography (CT) in six and magnetic resonance inserted, but visual failure continued and she underimaging (MRI) and magnetic resonance venography went right optic nerve sheath fenestration. Patient 13 (MRV) in nine. Autopsy confirmed CVT in the two underwent lumbar peritoneal shunt insertion comwho died.
bined with left optic nerve decompression. Patient 10's level of consciousness deteriorated despite intravenous heparin, and recombinant tissue plasminogen
Possible predisposing clinical risk factors
activator (rt-PA) was infused into the thrombosed Acquired risk factors with which CVT is associated superior sagittal (SST) sinus, but the patient died. were identified in 13/15 patients: the oral contraceptPatient 14 deteriorated despite intravenous heparin, ive pill in five, the puerperium in one, hormone rt-PA was infused into the thrombosed (SST), the replacement therapy in one, breast malignancy in patient recovered. one, mastoiditis in one, and dehydration due to proven salmonella food poisoning in one patient. In Outcome patient 1, the symptoms began during a lumbar myelogram using Omnipaque contrast media, which Ten patients recovered with no sequelae, and two although rare is a recognized cause.7 Patient 13 was patients died. Three patients were left with residual known to have Protein C deficiency but during unilateral ocular visual loss (blind eyes in two cases). investigation for CVT was found to have a lupus anticoagulant which remained positive on repeat testing. Patient 15 was demonstrated to have a lupus Discussion anticoagulant, but died before this could be further It was possible to attribute a clinical risk factor for confirmed.
CVT to 13/15 of the cases in this small retrospective series. In addition, 14% (2/14) were heterozygous
Primary prothrombotic risk factors
for the FVL mutation, although the overall frequency was not statistically significant. This differs from the Venous blood was available from 14 patients for mutation analysis (Table 2 ). All 14 were tested for high incidence of the FVL mutation found in a previous CVT series.1 None of our patients had the antithrombin III, protein C and S deficiency. No patient had evidence of antithrombin III or protein S prothrombin gene mutation G20210A compared to the 1.3% prevalence found in 300 controls in the deficiency. Patient 13 was already known to be protein-C-deficient, and this was confirmed. Mutation South Wales population, itself similar to the prevalence in healthy controls found by Poort,2 our results analysis for FVL(G1691A), G20201A and MTHFR C677T was by heteroduplex analysis.6 Two of 14 differ from the 6.3% mutation frequency detected by Poort2 in consecutive patients with a first episode of (14%) patients were heterozygous for the FVL mutation (G1691A, Arg506Gln) compared with 24/300 deep venous thrombosis. Mild hyperhomocystinaemia has been identified as a risk factor for venous (8%) of healthy controls (OR 1.92, 95%CI 0.46-9.07) 
